Arvinas (NASDAQ:ARVN) CAO David Loomis Sells 1,108 Shares

Arvinas, Inc. (NASDAQ:ARVN) CAO David Loomis sold 1,108 shares of Arvinas stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $12.16, for a total value of $13,473.28. Following the transaction, the chief accounting officer directly owned 29,692 shares in the company, valued at $361,054.72. The trade was a 3.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Arvinas Trading Down 1.2%

NASDAQ:ARVN traded down $0.16 on Thursday, reaching $13.14. 248,695 shares of the stock traded hands, compared to its average volume of 805,538. The firm has a market capitalization of $844.04 million, a price-to-earnings ratio of -10.27 and a beta of 1.88. Arvinas, Inc. has a 1-year low of $5.90 and a 1-year high of $18.93. The company’s 50 day moving average is $12.40 and its 200-day moving average is $10.53.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.55). Arvinas had a negative net margin of 30.77% and a negative return on equity of 13.22%. The firm had revenue of $9.50 million during the quarter, compared to the consensus estimate of $37.26 million. During the same period in the prior year, the company posted ($0.63) earnings per share. The company’s revenue for the quarter was down 84.0% compared to the same quarter last year. On average, equities research analysts forecast that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Trending Headlines about Arvinas

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Piper Sandler reiterated an “overweight” rating and raised its price target to $20, signaling significant upside from current levels. Piper Sandler raises PT to $20
• Positive Sentiment: Company guidance and commentary: Arvinas outlined 2026 clinical-data milestones and said it maintains a cash runway into the second half of 2028, which reduces near-term financing risk and supports ongoing pipeline programs. Arvinas outlines 2026 milestones & cash runway
• Positive Sentiment: Sector/pipeline coverage: Recent media coverage highlighted Arvinas’ promising PROTAC pipeline, which helped the stock move higher in futures earlier in the session. Coverage: Promising pipeline lifts futures
• Neutral Sentiment: Consensus/ratings: The consensus analyst view remains mixed — the street average is a “Hold,” so upgrades like Piper Sandler’s may not represent unanimous enthusiasm. Analyst consensus: Hold
• Neutral Sentiment: Short-interest data appears unreliable in the latest report (shows 0 shares and NaN). Given the data anomaly, short-squeeze/read-through risk is unclear until corrected figures are released. (No external link — data report entry)
• Negative Sentiment: Q4 earnings/revenue miss: Arvinas reported a sizable EPS and revenue shortfall for Q4 2025 — EPS missed estimates and revenue fell sharply year-over-year — which is the primary catalyst pressuring the stock. Q4 2025 earnings call transcript
• Negative Sentiment: Insider selling: CEO Randy Teel sold 4,786 shares and CAO David K. Loomis sold 1,108 shares on Feb 23, modestly reducing their holdings; such sales can be perceived negatively by investors even if they may be routine. CEO filing: CEO Form 4 — CAO filing: CAO Form 4

Institutional Trading of Arvinas

Institutional investors and hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC grew its stake in Arvinas by 491.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock valued at $43,000 after purchasing an additional 4,835 shares during the period. Canada Pension Plan Investment Board raised its position in Arvinas by 109.4% in the second quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock worth $49,000 after acquiring an additional 3,500 shares during the period. State of Wyoming purchased a new position in Arvinas in the third quarter valued at about $68,000. Abel Hall LLC purchased a new stake in shares of Arvinas during the 4th quarter worth approximately $125,000. Finally, Corient Private Wealth LLC bought a new stake in shares of Arvinas in the 4th quarter worth approximately $127,000. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on ARVN shares. Piper Sandler reiterated an “overweight” rating and issued a $20.00 target price (up from $16.00) on shares of Arvinas in a report on Wednesday. BTIG Research lifted their price objective on shares of Arvinas from $10.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Wedbush increased their target price on shares of Arvinas from $9.00 to $11.00 and gave the stock a “neutral” rating in a research note on Tuesday. Stephens raised their price target on shares of Arvinas from $14.00 to $15.00 and gave the stock an “overweight” rating in a report on Monday, November 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Arvinas in a report on Monday, December 22nd. Ten equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $13.47.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.